Real-world data and patient perspectives on quality care and maintenance therapy (MT) decision-making for recurrent ovarian cancer (ROC).

Authors

Robert Coleman

Robert L. Coleman

The University of Texas MD Anderson Cancer Center, Houston, TX

Robert L. Coleman , Rebecca R Crawford , Jeffrey D. Carter , Tamar Sapir

Organizations

The University of Texas MD Anderson Cancer Center, Houston, TX, PRIME Education, Fort Lauderdale, FL

Research Funding

Pharmaceutical/Biotech Company
This project was funded by an educational grant from TESARO. The study sponsor did not play a role in the design or analysis of the study or in the decision to submit for presentation.

Background: Despite clinical evidence illustrating the efficacy of MT for ROC, complexities, such as patient-, treatment-, and disease-related factors, and team-based care coordination, limit its optimal use in ROC. In a quality improvement (QI) program, conducted at 2 oncology systems, we evaluated gaps in evidence-based, quality ROC care. Methods: Between 09/2019-02/2020, retrospective EMR audits of 200 patients with ovarian cancer were analyzed for demographics, disease characteristics, treatment history, and shared decision-making (SDM) involving MT. Surveys were administered to evaluate challenges, barriers and experiences of healthcare professionals (HCP; N = 35) and their patients with ROC (N = 21). The HCP teams participated in audit-feedback sessions and developed action plans for resolving identified gaps. Results: EMR audits revealed low utility of MT among patients with ROC (Table), and only 20% of patients reported that MT was discussed as a treatment option. Lack of access to newer therapies was most commonly identified (27%) by HCP as the biggest challenge in treating patients with ROC. Furthermore, survey results revealed that HCP are challenged to correctly integrate guidelines for patient selection for PARP inhibitor MT based on BRCA mutation status (18% of HCP answered correctly), response to previous chemotherapy (49% correct), and line of therapy (46% correct). Data indicated a low level of SDM – none of the patients indicated a high level involvement in treatment decisions and only 20% indicated a high level of agreement that their care team understood their treatment goals. EMR audits also illustrate low documentation of multiple aspects of SDM (Table). Oncology team members formulated plans to develop guidance documents to assist in therapy sequencing and tools to improve patient education. Conclusions: Overall, data from this QI program indicate gaps, challenges, and barriers in evidence-based, MT decision-making and engagement of patients in SDM. These areas for improvement may be relevant for future interventions to improve the provision of quality ROC care.

EMR audit data.

MeasureDocumented EMRs, N = 200 (%)
Receipt of MT after documented response to chemotherapy (n = 135)39
Receipt of MT with PARP inhibitor after documented response to chemotherapy (n = 135)4
BRCA1/2 Testing30
Patients asked about treatment goalsa32
Patients asked about treatment expectationsa43
Patients counseled about treatment risks and benefitsa53

aAssessed by qualitative content analysis of progress notes

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Quality Improvement

Citation

J Clin Oncol 38: 2020 (suppl; abstr e19174)

DOI

10.1200/JCO.2020.38.15_suppl.e19174

Abstract #

e19174

Abstract Disclosures